Axsome Therapeutics Amplifies Alzheimer’s Awareness Campaign Amid Rising Dementia Crisis
Event summary
- Axsome Therapeutics joins advocacy groups to raise awareness during Alzheimer’s & Brain Awareness Month in June 2026.
- Company will participate in over 30 Walk to End Alzheimer’s events and light its NYC headquarters in purple.
- Alzheimer’s disease affects 7 million in the U.S., projected to rise to 13 million by 2050.
- Agitation affects up to 76% of Alzheimer’s patients, highlighting unmet treatment needs.
The big picture
Axsome’s campaign underscores the growing burden of Alzheimer’s disease, a market projected to expand significantly as the aging population rises. The company’s focus on agitation—a prevalent yet underserved symptom—aligns with broader industry trends toward targeted CNS therapies. With over 150 million Americans affected by neurological and psychiatric conditions, Axsome’s strategic partnerships could enhance its access to patient communities and clinical insights.
What we're watching
- Market Positioning
- Whether Axsome can leverage its advocacy efforts to strengthen its brand in the competitive Alzheimer’s treatment space.
- Regulatory Progress
- The pace at which Axsome advances its pipeline, particularly for agitation associated with dementia.
- Patient Engagement
- How Axsome’s community initiatives will impact patient recruitment for ongoing and future clinical trials.
Related topics